The Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
The Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.
BMC Urol. 2021 Apr 23;21(1):68. doi: 10.1186/s12894-021-00840-5.
Due to the invasiveness of prostate biopsy, a prediction model of the individual risk of a positive biopsy result could be helpful to guide clinical decision-making. Most existing models are based on transrectal ultrasonography (TRUS)-guided biopsy. On the other hand, transperineal template-guided prostate biopsy (TTPB) has been reported to be more accurate in evaluating prostate cancer. The objective of this study is to develop a prediction model of the detection of high-grade prostate cancer (HGPC) on initial TTPB.
A total of 1352 out of 3794 (35.6%) patients were diagnosed with prostate cancer, 848 of whom had tumour with Grade Group 2-5. Age, PSA, PV, DRE and f/t PSA are independent predictors of HGPC with p < 0.001. The model showed good discrimination ability (c-index 0.886) and calibration during internal validation and good clinical performance was observed through decision curve analysis. The external validation of CPCC-RC, an existing model, demonstrated that models based on TRUS-guided biopsy may underestimate the risk of HGPC in patients who underwent TTPB.
We established a prediction model which showed good discrimination ability and calibration in predicting the detection of HGPC by initial TTPB. This model can be used to aid clinical decision making for Chinese patients and other Asian populations with similar genomic backgrounds, after external validations are conducted to further confirm its clinical applicability.
由于前列腺活检具有侵袭性,因此可以建立一种预测个体阳性活检结果风险的模型,以辅助临床决策。大多数现有的模型都是基于经直肠超声引导活检(TRUS)的。另一方面,经会阴模板引导前列腺活检(TTPB)在评估前列腺癌方面被报道更准确。本研究的目的是建立一种预测初次 TTPB 中检测到高级别前列腺癌(HGPC)的模型。
在 3794 例患者中,共有 1352 例(35.6%)被诊断为前列腺癌,其中 848 例肿瘤分级为 2-5 级。年龄、PSA、PV、DRE 和 f/tPSA 是 HGPC 的独立预测因子,p<0.001。该模型在内部验证中显示出良好的区分能力(c 指数 0.886)和校准,通过决策曲线分析观察到良好的临床性能。对现有的 CPCC-RC 模型进行外部验证表明,基于 TRUS 引导活检的模型可能低估了接受 TTPB 治疗的患者中 HGPC 的风险。
我们建立了一个预测模型,该模型在预测初次 TTPB 检测到 HGPC 方面具有良好的区分能力和校准。在进行外部验证以进一步确认其临床适用性后,该模型可用于辅助中国患者和具有类似基因组背景的其他亚洲人群的临床决策。